RxDoctor Payments Data

Kevin Green, MD

Pulmonary Disease · Jupiter, FLNPI 1346602927

Payments from drug & device makers

$16,546in general payments, 2019–2025

Across 179 payments — averaging $92.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Sanofi$4K
  • Olympus Corporation Of The Americas$1K
  • Pulmonx Corporation$1K
  • AstraZeneca$709
  • Boehringer Ingelheim$587
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$3,16219%
  • Travel & lodging$3,43921%
  • Food & beverage$6,84241%
  • Education$3,10319%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,546 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$209,909
Medicare patients
627
Services billed
1,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$301,820
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$182,060
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$33,754
Breo ElliptaFluticasone/Vilanterol46$33,085
Spiriva RespimatTiotropium Bromide11$13,627
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$9,704
SymbicortBudesonide/Formoterol Fumarate16$7,323
Albuterol Sulfate HfaAlbuterol Sulfate133$3,852
Azelastine Hcl14$658
Montelukast Sodium39$420
Prednisone62$330
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$290
Methylprednisolone26$203
Fluticasone Propionate15$152
Levofloxacin27$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$587$325,15046 claims
GSKTrelegy Ellipta, Breo Ellipta$75$215,145190 claims
AstraZenecaBreztri Aerosphere, Symbicort$709$41,07741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →